Logo

Qiagen SARS-CoV-2 Primer Panel for NGS

Aug 19, 2020

Qiagen has launched the QiaSeq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome. The panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to study the epidemiology of virus outbreaks. The two-step process applies QiaSeq technologies to conduct reverse transcription and cDNA synthesis from viral RNA samples, followed by generation of libraries compatible with Illumina sequencers. The workflow is faster and has lower input requirements than hybrid captures solutions, Qiagen said. The panel is supported with software pipelines tailored to SARS-CoV-2 genome analysis using Qiagen's CLC Genomics Workbench.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.